Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of its antibiotic immunotherapy, CD201, for the treatment of life-threatening multi-drug resistant bacteria. CARB-X is the world’s largest public-private partnership focused on antibacterials.
Recent News and Insights
Cidara seeks to save or improve patients’ lives through the development of anti-infectives that transform the standard of care. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.
There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly those that are increasingly resistant to available treatments.
CD101 IV is a novel echinocandin antifungal with potent activity against Candida, Aspergillus and PCP. We are developing CD101 IV for once weekly use. We have completed Phase 1 trials and are currently conducting an international Phase 2 trial (STRIVE) in candidemia.
Cloudbreak™ / CD201
Cloudbreak is a proprietary immunotherapy discovery platform that has the potential to do for infectious disease what immunotherapy has done for cancer. CD201 is our lead Cloudbreak candidate intended to direct a patient’s immune cells to attack bacterial infections.